Compare TRVG & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | IFRX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | Germany | Germany |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.4M | 303.4M |
| IPO Year | 2015 | 2017 |
| Metric | TRVG | IFRX |
|---|---|---|
| Price | $5.45 | $1.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.95 | ★ $6.25 |
| AVG Volume (30 Days) | 119.5K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $0.74 |
| 52 Week High | $5.70 | $2.95 |
| Indicator | TRVG | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 41.44 |
| Support Level | $2.78 | $0.87 |
| Resistance Level | $5.70 | $1.94 |
| Average True Range (ATR) | 0.33 | 0.20 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 53.52 | 3.73 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.